Details of the Drug

General Information of Drug (ID: DM06HG5)

Drug Name

Levomethadyl Acetate

Synonyms

LAAM; Levacetilmetadol; Levacetylmethadol; Levacetylmethadolum; Levomethadyl; Orlaam; Levacetylmethadol [INN]; Levacetilmetadol [INN-Spanish]; Levacetylmethadol (INN); Levacetylmethadolum [INN-Latin]; Levo-Alphacetylmethadol; Levo-Methadyl acetate; Levomethadyl acetate (USAN); Orlaam (TN); A-l-acetylmethadol; Alpha-l-Acetylmethadol; L-alpha-Acetylmethadol; Levo-alpha-Acetylmethadol; N-alpha-Acetylmethadol; Alpha-(-)-Acetylmethadol; [(3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate; [S-(R*,R*)]-beta-[2-Dimethylamino)propyl]-alpha-ethyl-beta-phenylbenzeneethanol acetate (ester); Benzeneethanol, beta-[(2S)-2-(dimethylamino)propyl]-alpha-ethyl-beta-phenyl-, acetate (ester), (alphaS)-(9CI); (-)-alpha-Acetylmethadol; (1S,4S)-4-(dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate; (3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-2-yl acetate; 1-alpha-Acetylmethadol; 3-Heptanol, 6-(dimethylamino)-4,4-diphenyl-, acetate (ester), (3S,6S)-(-)-(8CI)

Indication

Disease Entry	ICD 11	Status	REF
Opioid dependence	6C43.2Z	Approved	[1], [2]

Therapeutic Class

Analgesics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

353.5

Topological Polar Surface Area (xlogp)

4.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Clearance: The drug present in the plasma can be removed from the body at the rate of 5.4 mL/min/kg [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 18 hours [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 11.31513 micromolar/kg/day [4]
Unbound Fraction: The unbound fraction of drug in plasma is 0.2% [3]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 8.3 L/kg [3]

Chemical Identifiers

Formula: C23H31NO2
IUPAC Name: [(3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate
Canonical SMILES: CC[C@@H](C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C
InChI: InChI=1S/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3/t18-,22-/m0/s1
InChIKey: XBMIVRRWGCYBTQ-AVRDEDQJSA-N

Cross-matching ID

PubChem CID: 15130
ChEBI ID: CHEBI:6441
CAS Number: 1477-40-3
DrugBank ID: DB01227
TTD ID: D05PIZ

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Opioid receptor mu (MOP)	TTKWM86	OPRM_HUMAN	Agonist	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Opioid dependence

ICD Disease Classification

6C43.2Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Opioid receptor mu (MOP)	DTT	OPRM1	5.94E-01	-0.02	-0.17

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Levomethadyl Acetate

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Lofexidine	DM1WXA6	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Lofexidine.	Opioid use disorder [6C43]	[16]
-----------

Coadministration of a Drug Treating the Disease Different from Levomethadyl Acetate (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Ivosidenib.	Acute myeloid leukaemia [2A60]	[16]
Midostaurin	DMI6E0R	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Midostaurin.	Acute myeloid leukaemia [2A60]	[16]
Arn-509	DMT81LZ	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Arn-509.	Acute myeloid leukaemia [2A60]	[16]
Gilteritinib	DMWQ4MZ	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Gilteritinib.	Acute myeloid leukaemia [2A60]	[16]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Oliceridine.	Acute pain [MG31]	[16]
Mepyramine	DMB4SFH	Major	Additive CNS depression effects by the combination of Levomethadyl Acetate and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[17]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Levomethadyl Acetate and Ivabradine.	Angina pectoris [BA40]	[16]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Dronedarone.	Angina pectoris [BA40]	[18]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[16]
Posaconazole	DMUL5EW	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Posaconazole.	Aspergillosis [1F20]	[16]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Levomethadyl Acetate and Levalbuterol.	Asthma [CA23]	[19]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Pirbuterol.	Asthma [CA23]	[19]
Lisdexamfetamine	DM6W8V5	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[16]
Dalfopristin	DM4LTKV	Major	Decreased metabolism of Levomethadyl Acetate caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[20]
Retigabine	DMGNYIH	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Retigabine.	Behcet disease [4A62]	[16]
Cariprazine	DMJYDVK	Major	Additive CNS depression effects by the combination of Levomethadyl Acetate and Cariprazine.	Bipolar disorder [6A60]	[21]
Erdafitinib	DMI782S	Moderate	Increased metabolism of Levomethadyl Acetate caused by Erdafitinib mediated induction of CYP450 enzyme.	Bladder cancer [2C94]	[22]
Pexidartinib	DMS2J0Z	Major	Increased metabolism of Levomethadyl Acetate caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[23]
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Eribulin.	Breast cancer [2C60-2C6Y]	[16]
Lapatinib	DM3BH1Y	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Lapatinib.	Breast cancer [2C60-2C6Y]	[16]
Tucatinib	DMBESUA	Major	Decreased metabolism of Levomethadyl Acetate caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[20]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Levomethadyl Acetate caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[24]
Bosutinib	DMTI8YE	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Bosutinib.	Breast cancer [2C60-2C6Y]	[16]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[16]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[19]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[19]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Levomethadyl Acetate and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[19]
Arformoterol	DMYM974	Moderate	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[19]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Levomethadyl Acetate and Dihydrocodeine.	Chronic pain [MG30]	[21]
Levomilnacipran	DMV26S8	Moderate	Additive serotonergic effects by the combination of Levomethadyl Acetate and Levomilnacipran.	Chronic pain [MG30]	[25]
Panitumumab	DMQPD1F	Major	Increased risk of ventricular arrhythmias by the combination of Levomethadyl Acetate and Panitumumab.	Colorectal cancer [2B91]	[26]
Sevoflurane	DMC9O43	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Sevoflurane.	Corneal disease [9A76-9A78]	[16]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Pasireotide.	Cushing syndrome [5A70]	[16]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Osilodrostat.	Cushing syndrome [5A70]	[16]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Levomethadyl Acetate caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[23]
MK-8228	DMOB58Q	Major	Decreased metabolism of Levomethadyl Acetate caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[20]
Vilazodone	DM4LECQ	Moderate	Additive serotonergic effects by the combination of Levomethadyl Acetate and Vilazodone.	Depression [6A70-6A7Z]	[25]
Vortioxetine	DM6F1PU	Moderate	Additive serotonergic effects by the combination of Levomethadyl Acetate and Vortioxetine.	Depression [6A70-6A7Z]	[25]
Milnacipran	DMBFE74	Moderate	Additive CNS depression effects by the combination of Levomethadyl Acetate and Milnacipran.	Depression [6A70-6A7Z]	[27]
Desvenlafaxine	DMHD4PE	Major	Additive CNS depression effects by the combination of Levomethadyl Acetate and Desvenlafaxine.	Depression [6A70-6A7Z]	[17]
OPC-34712	DMHG57U	Major	Additive CNS depression effects by the combination of Levomethadyl Acetate and OPC-34712.	Depression [6A70-6A7Z]	[21]
Clomipramine	DMINRKW	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Clomipramine.	Depression [6A70-6A7Z]	[16]
Esketamine	DMVU687	Major	Additive CNS depression effects by the combination of Levomethadyl Acetate and Esketamine.	Depression [6A70-6A7Z]	[17]
Mepenzolate	DM8YU2F	Moderate	Additive antimotility effects by the combination of Levomethadyl Acetate and Mepenzolate.	Digestive system disease [DE2Z]	[28]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[16]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Deutetrabenazine.	Dystonic disorder [8A02]	[16]
Ingrezza	DMVPLNC	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Ingrezza.	Dystonic disorder [8A02]	[16]
Cenobamate	DMGOVHA	Major	Increased metabolism of Levomethadyl Acetate caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[23]
Stiripentol	DMMSDOY	Major	Decreased metabolism of Levomethadyl Acetate caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[20]
Fosphenytoin	DMOX3LB	Major	Increased metabolism of Levomethadyl Acetate caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[23]
Rufinamide	DMWE60C	Major	Additive CNS depression effects by the combination of Levomethadyl Acetate and Rufinamide.	Epilepsy/seizure [8A61-8A6Z]	[17]
Eslicarbazepine	DMZREFQ	Major	Increased metabolism of Levomethadyl Acetate caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[23]
Cannabidiol	DM0659E	Major	Additive CNS depression effects by the combination of Levomethadyl Acetate and Cannabidiol.	Epileptic encephalopathy [8A62]	[17]
Tazemetostat	DMWP1BH	Major	Increased metabolism of Levomethadyl Acetate caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[23]
Solifenacin	DMG592Q	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Solifenacin.	Functional bladder disorder [GC50]	[16]
Sunitinib	DMCBJSR	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[16]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Levomethadyl Acetate caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Fostemsavir	DM50ILT	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[16]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Levomethadyl Acetate caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Saquinavir	DMG814N	Major	Decreased metabolism of Levomethadyl Acetate caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Levomethadyl Acetate caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[29]
Rilpivirine	DMJ0QOW	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[16]
Darunavir	DMN3GCH	Major	Decreased metabolism of Levomethadyl Acetate caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Belladonna	DM2RBWK	Moderate	Additive CNS depression effects by the combination of Levomethadyl Acetate and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[30]
Suvorexant	DM0E6S3	Major	Additive CNS depression effects by the combination of Levomethadyl Acetate and Suvorexant.	Insomnia [7A00-7A0Z]	[21]
Amobarbital	DM0GQ8N	Major	Additive CNS depression effects by the combination of Levomethadyl Acetate and Amobarbital.	Insomnia [7A00-7A0Z]	[21]
Tasimelteon	DMLOQ1V	Major	Additive CNS depression effects by the combination of Levomethadyl Acetate and Tasimelteon.	Insomnia [7A00-7A0Z]	[21]
ITI-007	DMUQ1DO	Major	Additive CNS depression effects by the combination of Levomethadyl Acetate and ITI-007.	Insomnia [7A00-7A0Z]	[21]
Quazepam	DMY4D87	Major	Additive CNS depression effects by the combination of Levomethadyl Acetate and Quazepam.	Insomnia [7A00-7A0Z]	[21]
Polyethylene glycol	DM4I1JP	Major	Increased risk of ventricular arrhythmias by the combination of Levomethadyl Acetate and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[31]
Remimazolam	DMLVSYX	Major	Additive CNS depression effects by the combination of Levomethadyl Acetate and Remimazolam.	Labour/delivery anaesthesia complication [JB0C]	[21]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Crizotinib.	Lung cancer [2C25]	[16]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Levomethadyl Acetate caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[32]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Ceritinib.	Lung cancer [2C25]	[16]
PF-06463922	DMKM7EW	Major	Increased metabolism of Levomethadyl Acetate caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[23]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Osimertinib.	Lung cancer [2C25]	[16]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Selpercatinib.	Lung cancer [2C25]	[16]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Lumefantrine.	Malaria [1F40-1F45]	[16]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Hydroxychloroquine.	Malaria [1F40-1F45]	[16]
Inotuzumab ozogamicin	DMAC130	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[16]
Idelalisib	DM602WT	Major	Decreased metabolism of Levomethadyl Acetate caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[20]
IPI-145	DMWA24P	Major	Decreased metabolism of Levomethadyl Acetate caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[20]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Vemurafenib.	Melanoma [2C30]	[16]
LGX818	DMNQXV8	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and LGX818.	Melanoma [2C30]	[16]
Dabrafenib	DMX6OE3	Major	Increased metabolism of Levomethadyl Acetate caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[23]
Danazol	DML8KTN	Major	Decreased metabolism of Levomethadyl Acetate caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[20]
Allopregnanolone	DMNLHAC	Major	Additive CNS depression effects by the combination of Levomethadyl Acetate and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[17]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Levomethadyl Acetate caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[33]
Flibanserin	DM70DTN	Major	Additive CNS depression effects by the combination of Levomethadyl Acetate and Flibanserin.	Mood disorder [6A60-6E23]	[17]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Panobinostat.	Multiple myeloma [2A83]	[16]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Levomethadyl Acetate and Siponimod.	Multiple sclerosis [8A40]	[34]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Levomethadyl Acetate and Fingolimod.	Multiple sclerosis [8A40]	[18]
Ozanimod	DMT6AM2	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Ozanimod.	Multiple sclerosis [8A40]	[16]
Romidepsin	DMT5GNL	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Romidepsin.	Mycosis fungoides [2B01]	[16]
Fedratinib	DM4ZBK6	Major	Decreased metabolism of Levomethadyl Acetate caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[20]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Nilotinib.	Myeloproliferative neoplasm [2A20]	[16]
Dasatinib	DMJV2EK	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Dasatinib.	Myeloproliferative neoplasm [2A20]	[16]
Prasugrel	DM7MT6E	Moderate	Altered absorption of Levomethadyl Acetate due to GI dynamics variation caused by Prasugrel.	Myocardial infarction [BA41-BA43]	[34]
Netupitant	DMEKAYI	Major	Decreased metabolism of Levomethadyl Acetate caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[20]
Metoclopramide	DMFA5MY	Moderate	Antagonize the effect of Levomethadyl Acetate when combined with Metoclopramide.	Nausea/vomiting [MD90]	[35]
Entrectinib	DMMPTLH	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Entrectinib.	Non-small cell lung cancer [2C25]	[16]
Polythiazide	DMCH80F	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Polythiazide.	Oedema [MG29]	[26]
Olaparib	DM8QB1D	Moderate	Decreased metabolism of Levomethadyl Acetate caused by Olaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[34]
Rucaparib	DM9PVX8	Major	Decreased metabolism of Levomethadyl Acetate caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[20]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Triclabendazole.	Parasitic worm infestation [1F90]	[16]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Levomethadyl Acetate caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[36]
Methylscopolamine	DM5VWOB	Moderate	Additive CNS depression effects by the combination of Levomethadyl Acetate and Methylscopolamine.	Peptic ulcer [DA61]	[30]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[37]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Lefamulin.	Pneumonia [CA40]	[16]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Levomethadyl Acetate caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[20]
Degarelix	DM3O8QY	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Degarelix.	Prostate cancer [2C82]	[16]
ABIRATERONE	DM8V75C	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and ABIRATERONE.	Prostate cancer [2C82]	[16]
Enzalutamide	DMGL19D	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Enzalutamide.	Prostate cancer [2C82]	[16]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Levomethadyl Acetate and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[38]
Dexamethasone	DMMWZET	Major	Increased metabolism of Levomethadyl Acetate caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[23]
Aripiprazole	DM3NUMH	Major	Additive CNS depression effects by the combination of Levomethadyl Acetate and Aripiprazole.	Schizophrenia [6A20]	[21]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Iloperidone.	Schizophrenia [6A20]	[16]
Paliperidone	DM7NPJS	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Paliperidone.	Schizophrenia [6A20]	[16]
Molindone	DMAH70G	Major	Additive CNS depression effects by the combination of Levomethadyl Acetate and Molindone.	Schizophrenia [6A20]	[21]
Thiothixene	DMDINC4	Major	Additive CNS depression effects by the combination of Levomethadyl Acetate and Thiothixene.	Schizophrenia [6A20]	[21]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Amisulpride.	Schizophrenia [6A20]	[16]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Asenapine.	Schizophrenia [6A20]	[16]
Voxelotor	DMCS6M5	Major	Decreased metabolism of Levomethadyl Acetate caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[20]
Telotristat ethyl	DMDIYFZ	Major	Increased metabolism of Levomethadyl Acetate caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[23]
Larotrectinib	DM26CQR	Major	Decreased metabolism of Levomethadyl Acetate caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[20]
Armodafinil	DMGB035	Major	Increased metabolism of Levomethadyl Acetate caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[23]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[16]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[16]
Triptorelin	DMTK4LS	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[16]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Pitolisant.	Somnolence [MG42]	[16]
Telavancin	DM58VQX	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[16]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Levomethadyl Acetate caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[39]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Levomethadyl Acetate caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[16]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Lenvatinib.	Thyroid cancer [2D10]	[16]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Levomethadyl Acetate and Cabozantinib.	Thyroid cancer [2D10]	[16]
Elagolix	DMB2C0E	Major	Increased metabolism of Levomethadyl Acetate caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[23]
-----------


⏷ Show the Full List of 136 DDI Information of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7212).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020315.
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5	Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci. 2000;909:186-216.
6	Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8.
7	Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8.
8	Clinical pipeline report, company report or official report of signaturerx.
9	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
10	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
11	Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.
12	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
13	Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
14	Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
15	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
16	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
17	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
18	Canadian Pharmacists Association.
19	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
20	Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
21	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
22	Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
23	Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
24	Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
25	Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
26	Cohen J "Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents." Am Heart J 122 (1991): 919-25. [PMID: 1678923]
27	Das PK, Warkentin DI, Hewko R, Forrest DL "Serotonin syndrome after concomitant treatment with linezolid and meperidine." Clin Infect Dis 46 (2008): 264-5. [PMID: 18171260]
28	Product Information. Lortab (acetaminophen-hydrocodone). Akorn Inc, Buffalo Grove, IL.
29	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
30	Product Information. Exalgo (hydromorphone). Covidien, Mansfield, MA.
31	Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
32	Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
33	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
34	Cerner Multum, Inc. "Australian Product Information.".
35	Manara AR, Shelly MP, Quinn K, Park GR "The effect of metoclopramide on the absorption of oral controlled release morphine." Br J Clin Pharmacol 25 (1988): 518-21. [PMID: 3382595]
36	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
37	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
38	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
39	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.